{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:12Z","timestamp":1792928832878,"version":"4.5.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed\/refractory large B-cell lymphoma (R\/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene ciloleucel (axi-cel) vs SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and \u22651 follow-up PRO completion. Prespecified hypotheses for Quality of Life Questionnaire-Core 30 (QLQ-C30) physical functioning, global health status\/QoL, and EQ-5D-5L visual analog scale (VAS) were tested using mixed-effects models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 global health status\/QoL (estimated difference 18.1 [95% confidence interval (CI), 12.3-23.9]), physical functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P &amp;lt; .0001 for all). At day 150, scores significantly favored axi-cel vs SOC for global health status\/QoL (9.8 [95% CI, 2.6-17.0]; P\u00a0= .0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P\u00a0= .0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R\/R LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03391466.<\/jats:p>","DOI":"10.1182\/blood.2022015478","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T16:16:43Z","timestamp":1657901803000},"page":"2248-2260","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma"],"prefix":"10.1182","volume":"140","author":[{"given":"Mahmoud","family":"Elsawy","sequence":"first","affiliation":[{"name":"1Queen Elizabeth II Health Sciences Centre and Division of Hematology, Department of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"2Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"3Hematology Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Larouche","sequence":"additional","affiliation":[{"name":"4Centre Hospitalier Universitaire (CHU) de Qu\u00e9bec, H\u00f4pital de l'Enfant-J\u00e9sus, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Wannesson","sequence":"additional","affiliation":[{"name":"5Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cwynarski","sequence":"additional","affiliation":[{"name":"6Department of Haematology, University College London Hospitals National Health Services (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Osman","sequence":"additional","affiliation":[{"name":"7Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Davison","sequence":"additional","affiliation":[{"name":"8Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob D.","family":"Rudzki","sequence":"additional","affiliation":[{"name":"9Department of Hematology & Oncology, The Medical University of Innsbruck, University Clinic for Internal Medicine, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"10Greenebaum Comprehensive Cancer Center, Transplant and Cellular Therapy Program, University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8573","authenticated-orcid":false,"given":"Kathleen","family":"Dorritie","sequence":"additional","affiliation":[{"name":"11University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-2554","authenticated-orcid":false,"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[{"name":"12Comprehensive Cancer Center, Blood and Marrow Transplant Program, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"13Division of Cancer Sciences, The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"14Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, University of Lille, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"15The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Martin Garcia-Sancho","sequence":"additional","affiliation":[{"name":"16Hematology Department, Salamanca University Hospital, Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4428","authenticated-orcid":false,"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[{"name":"17Moores Cancer Center, University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Ulrickson","sequence":"additional","affiliation":[{"name":"18Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-0855","authenticated-orcid":false,"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[{"name":"20The Ottawa Hospital, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"21University of Paris, H\u00f4pital Saint-Louis, Hemato-Oncology, DMU DHI, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[{"name":"22Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"23Department of Medicine, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[{"name":"24Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"},{"name":"25University Hospitals Birmingham NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Joshi","sequence":"additional","affiliation":[{"name":"26OPEN Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jhih","family":"Wang","sequence":"additional","affiliation":[{"name":"26OPEN Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-8052","authenticated-orcid":false,"given":"Caitlyn T.","family":"Solem","sequence":"additional","affiliation":[{"name":"26OPEN Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-4863","authenticated-orcid":false,"given":"Julia Thornton","family":"Snider","sequence":"additional","affiliation":[{"name":"27Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[{"name":"27Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"To","sequence":"additional","affiliation":[{"name":"27Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"28Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC on behalf of Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)\/ Lunenburg Lymphoma Phase 1 \/ II Consortium (LLPC), University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2022112416255040100_bib1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2022112416255040100_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A\u00a0review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"2022112416255040100_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2022112416255040100_bib4","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2022112416255040100_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2022112416255040100_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"2022112416255040100_bib7","author":"YESCARTA\u00ae (axicabtagene ciloleucel) Prescribing information","year":"2021"},{"key":"2022112416255040100_bib8","author":"YESCARTA\u00ae (axicabtagene ciloleucel) [summary of product characteristics]","year":"2021"},{"issue":"1","key":"2022112416255040100_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2022112416255040100_bib10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2022112416255040100_bib11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2022112416255040100_bib12","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-014-2099-8","article-title":"Health-related quality of life and persistent symptoms in relation to (R-) CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Ann Hematol"},{"issue":"4","key":"2022112416255040100_bib13","first-page":"679","article-title":"Definitive salvage chemotherapy for the treatment of refractory\/relapsed non-Hodgkin lymphoma, a single center experience","volume":"54","author":"Hafez","year":"2018","journal-title":"Alex J Med"},{"key":"2022112416255040100_bib14","unstructured":"Food and Drug Administration . Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed 23 May 2022. https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"2022112416255040100_bib15","unstructured":"Food and Drug Administration . Core Patient-Reported Outcomes in Cancer Clinical Trials. Accessed 23 May 2022. https:\/\/fda.report\/media\/149994\/Core-Patient-Reported-Outcomes-in-Cancer-Clinical-Trials_508ed.pdf."},{"key":"2022112416255040100_bib16","unstructured":"European Medicines Agency . Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies. Accessed 23 May 2022. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf."},{"issue":"5","key":"2022112416255040100_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"2022112416255040100_bib18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2022112416255040100_bib19","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","article-title":"A\u00a0preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"15 suppl","key":"2022112416255040100_bib20","doi-asserted-by":"crossref","first-page":"e20070","DOI":"10.1200\/JCO.2020.38.15_suppl.e20070","article-title":"Health-related quality of life (HRQOL) burden in patients with relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin\u2019s lymphoma (RR-NHL)","volume":"38","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2022112416255040100_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"11","key":"2022112416255040100_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/fon-2020-0946","article-title":"Health-related quality of life and utility outcomes with selinexor in relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"2022112416255040100_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjh.16300","article-title":"Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study","volume":"189","author":"Thieblemont","year":"2020","journal-title":"Br J Haematol"},{"key":"2022112416255040100_bib24","author":"Fayers","year":"2001","edition":"3rd Edition"},{"issue":"10","key":"2022112416255040100_bib25","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"2022112416255040100_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with car T-cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"issue":"20","key":"2022112416255040100_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"2022112416255040100_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2022112416255040100_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"2022112416255040100_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"issue":"1","key":"2022112416255040100_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0R Stat Soc Series B Stat Methodol"},{"issue":"11","key":"2022112416255040100_bib32","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00520-010-1016-5","article-title":"EORTC PROBE project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support Care Cancer"},{"issue":"1","key":"2022112416255040100_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2022112416255040100_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2022112416255040100_bib35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"15","key":"2022112416255040100_bib36","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"2022112416255040100_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"issue":"446","key":"2022112416255040100_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"suppl_1","key":"2022112416255040100_bib39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2019-121715","article-title":"Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: Longitudinal patient reported adverse events, cognition and quality of life","volume":"134","author":"Sidana","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022112416255040100_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ibd.20989","article-title":"Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany","volume":"16","author":"Stark","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2022112416255040100_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"EORTC Quality of Life Group. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"2022112416255040100_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2022112416255040100_bib43","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2022112416255040100_bib44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2022112416255040100_bib45","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2022112416255040100_bib46","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1182\/blood-2021-151611","article-title":"Improved quality of life (QOL) with lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, compared with standard of care (SOC) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 3 Transform study","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2022112416255040100_bib47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2022112416255040100_bib48","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/21\/2248\/2018730\/blood_bld-2022-015478-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/21\/2248\/2018730\/blood_bld-2022-015478-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T02:40:53Z","timestamp":1727577653000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/21\/2248\/485937\/Patient-reported-outcomes-in-ZUMA-7-a-phase-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":48,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015478","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}